MCP-1 as a Target for Diagnosis and Treatment of Chronic Prostatitis/Chronic Pelvic Pain Syndrome
- Technology Benefits
- • Existing murine models • Existing preclinical data • Potential for multiple indications
- Detailed Technology Description
- Microbial modulation of immunity and pain resulting from urinary tract infection.#pain #chronic #therapeutics #biomarker #vaccine
- *Abstract
-
Northwestern researchers have developed therapies to treat urinary tract infection (UTI). They use novel UTI therapeutic approaches by targeting the cell-mediated response instead of the humoral responses, which is the current focus today. They created an attenuated-live UTI vaccine that confers protective immunity. In fact, it skews responses to also eradicate intracellular pathogens that contribute to recurrent UTI. The same researchers have also developed therapies to reduce pelvic pain conditions, using both a small-molecule approach and a probiotic approach. They already have preclinical data for a co-formulation of re-purposed generic to target chronic pelvic pain in males. They also have very effective probiotics for female pelvic pain, a platform with the potential for multiple indications.
- *Inventors
- David Klumpp* Anthony Schaeffer* Praveen Thumbikat
- Country/Region
- USA
